Citations

Clear

3942 citation(s) found for "To, Van".

Comment: Longevity gene KLOTHO may play a role in Alzheimer disease
Harten, Argonde C. van , van Harten, Argonde C

Mayo Clinic

Neurology | March 14, 2019 | Volume: 92 | Issue: 16 | Pages: 751-751

10.1212/wnl.0000000000007302 | PMID 30867268 Get It

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Gelman, Rebecca , Anders, Carey K. , Melisko, Michelle , Parsons, Heather A. , Cropp, Anne B., Silvestri, Kelly M., Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisín M. , Poznak, Catherine Van , Blackwell, Kimberly , Puhalla, Shannon L. , Jankowitz, Rachel C. , Ibrahim, Nuhad K. , Moynihan, Timothy J. , O’Sullivan, Ciara C. , Nangia, Julie R. , Pohlmann, Paula R. , Burns, Robyn, Rimawi, Mothaffar F. , Krop, Ian E. , O'Sullivan, Ciara C, Rimawi, Mothaffar , Freedman, Rachel A. , Moy, Beverly , Smith, Karen L. , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1081-1089

10.1200/jco.18.01511 | PMID 30860945 Get It

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.
Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2015.33.15_suppl.503 Get It

Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.
Renfro, Lindsay A. , Haller, Daniel G. , Twelves, Chris , Guthrie, Katherine A. , Gramont, Aimery de , Allegra, Carmen J. , Group, ACCENT Collaborative, Cheung, Winson Y. , Yothers, Greg , Gray, Richard , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Grothey, Axel , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Sargent, Daniel J. , Group, ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6580-6580

10.1200/jco.2015.33.15_suppl.6580 Get It

Contemporary national trends of prostate cancer screening among privately insured patients in the United States.
Kim, Simon P. , Karnes, Jeffrey , Gross, Cary P. , Meropol, Neal J. , Houten, Holly K. Van , Abouassaly, Robert , Shah, Nilay D.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5065-5065

10.1200/jco.2015.33.15_suppl.5065 Get It

Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Barrios, Pablo M. , Albigès, Laurence , Krajewski, Katherine M. , Pal, Sumanta K. , Heng, Daniel Yick Chin, Kwiatkowski, David J. , Thorner, Aaron R. , Rini, Brian I. , Agarwal, Neeraj , Ho, Thai H. , Van Allen, Eliezer M , Porta, Camillo , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4519-4519

10.1200/jco.2015.33.15_suppl.4519 Get It

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.
Pavel, Marianne, Lam, Du, Kunz, Tiffany, Brandt, Ulrike , Capdevila, Jaume , Tomassetti, Paola, Hobday, Timothy J. , Pommier, Rodney F. , Lombard‐Bohas, Catherine , Cutsem, Eric Van , Vries, Elisabeth G.E. de , Yao, James C.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4091-4091

10.1200/jco.2015.33.15_suppl.4091 Get It

Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
Grothey, Axel, Humblet, Yves, Mineur, Laurent , Adenis, Antoine , Lenz, Heinz‐Josef , Goldberg, Richard M. , Wagner, Andrea, Falcone, Alfredo , Bouché, Olivier , Tabernero, Josep , Yoshino, Takayuki , Xu, Lei , Wagner, Andrea, Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e14579-e14579

10.1200/jco.2015.33.15_suppl.e14579 Get It

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.
Teufel, Michael, Schwenke, Susanne, Beckmann, Georg, Reischl, Joachim, Vonk, Richardus , Lenz, Heinz‐Josef , Jeffers, Michael , Wilhelm, Scott M., Wagner, Andrea, Laurent, Dirk, Kobina, Svetlana, Rutstein, Mark, Wirapati, Pratyaksha , Seidel, Henrik , Tabernero, Josep , Siena, Salvatore , Grothey, Axel , Cutsem, Eric Van , Wagner, Andrea, Guinney, Justin , Tejpar, Sabine

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3558-3558

10.1200/jco.2015.33.15_suppl.3558 Get It